0.8201
price down icon5.60%   -0.0487
after-market Dopo l'orario di chiusura: .80 -0.02 -2.44%
loading
Precedente Chiudi:
$0.8687
Aprire:
$0.8467
Volume 24 ore:
435.98K
Relative Volume:
0.09
Capitalizzazione di mercato:
$10.91M
Reddito:
-
Utile/perdita netta:
$-29.77M
Rapporto P/E:
-0.0536
EPS:
-15.2954
Flusso di cassa netto:
$-24.23M
1 W Prestazione:
-21.15%
1M Prestazione:
-24.07%
6M Prestazione:
-65.25%
1 anno Prestazione:
-84.53%
Intervallo 1D:
Value
$0.76
$0.8467
Intervallo di 1 settimana:
Value
$0.76
$1.04
Portata 52W:
Value
$0.3975
$5.91

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name
Nome
Moleculin Biotech Inc
Name
Telefono
713-300-5160
Name
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Name
Dipendente
17
Name
Cinguettio
@moleculinbio
Name
Prossima data di guadagno
2024-12-08
Name
Ultimi documenti SEC
Name
MBRX's Discussions on Twitter

Confronta MBRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MBRX
Moleculin Biotech Inc
0.8201 10.91M 0 -29.77M -24.23M -15.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-12 Downgrade Maxim Group Buy → Hold
2022-07-18 Ripresa Oppenheimer Outperform

Moleculin Biotech Inc Borsa (MBRX) Ultime notizie

pulisher
Apr 02, 2025

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo

Apr 02, 2025
pulisher
Apr 01, 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan

Apr 01, 2025
pulisher
Mar 29, 2025

Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN

Mar 29, 2025
pulisher
Mar 28, 2025

What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq

Mar 26, 2025
pulisher
Mar 25, 2025

H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: P - GuruFocus

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Inc Reports Q4 Earnings: EPS of -$1.28, Revenue at $0 Million, Aligns with Analyst Estimates - GuruFocus

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Shares Corporate Presentation Update - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

FDA-Optimized Phase 3 AML Trial: Moleculin Cuts Costs, Expands to Europe - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... By GuruFocus - Investing.com Canada

Mar 24, 2025
pulisher
Mar 21, 2025

Moleculin Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Moleculin Biotech, Inc. SEC 10-K Report - TradingView

Mar 21, 2025
pulisher
Mar 19, 2025

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire

Mar 19, 2025
pulisher
Mar 18, 2025

Moleculin Biotech Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView

Mar 18, 2025
pulisher
Mar 13, 2025

Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference - PR Newswire

Mar 11, 2025
pulisher
Mar 11, 2025

5 Major Growth Catalysts: Moleculin Biotech CEO Reveals 2025 Strategic Roadmap - Stock Titan

Mar 11, 2025
pulisher
Mar 10, 2025

Moleculin to Present at the 37th Annual ROTH Conference - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

Moleculin to Present at the 37th Annual ROTH Conference -March 10, 2025 at 08:46 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds - GuruFocus.com

Mar 10, 2025
pulisher
Mar 06, 2025

Soft Tissue Sarcoma Market on Track for Major Expansion by 2032, According to DelveInsight | Moleculin Biotech - openPR

Mar 06, 2025
pulisher
Mar 06, 2025

Moleculin Announces Additional Annamycin Patent Allowances to En - GuruFocus.com

Mar 06, 2025
pulisher
Mar 06, 2025

Moleculin Biotech Inc Announces Additional Annamycin Patent Allowances To Enhance Global Exclusivity - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Moleculin Biotech to be granted new patents for Annamycin - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - PR Newswire

Mar 06, 2025
pulisher
Mar 06, 2025

What is HC Wainwright’s Forecast for MBRX Q4 Earnings? - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World

Mar 05, 2025

Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):